Why the study?
Cardiovascular side-effects of cancer therapies can occur early or decades later, impairing quality of life and overall survival, making knowledge, early detection, and treatment of cardiotoxicity essential.
This review emphasizes the critical role of the cardio-oncology subspecialty in the early detection and management of cardiovascular complications arising from modern cancer treatments.
Answers are grounded in this paper and cite their sources.
Supports integrated cardio-oncology care during cancer therapy; leaves open optimal surveillance protocols pending prospective trials.
Modern treatment strategies have improved prognosis and survival of patients with malignant diseases. The key components of tumor treatment are conventional chemotherapy, radiotherapy, targeted therapies, and immunotherapy. Cardiovascular side-effects may occur in the early phase of tumor therapy or even decades later. Therefore, knowledge and awareness of acute and long-lasting cardiac side effects of anti-cancer therapies are essential. Cardiotoxicity impairs quality of life and overall survival. The new cardiologic subspecialty 'cardio-oncology' deals with the different cardiovascular problems arising from tumor treatment and the relationship between cancer and heart diseases. Early detection and treatment of cardiotoxicity is of crucial importance. A detailed cardiac assessment of patients prior to administration of cardiotoxic agents, during and after treatment should be performed in all patients. The current review focusses on acute and long-term cardiotoxic side effects of classical cytotoxic and selected modern drug treatments such as immune checkpoint inhibitors and discusses strategies for the diagnosis of treatment-related adverse cardiovascular effects in cancer patients.
No takes yet. Share an insight, caveat, or question.
Wall et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: